Too Big To Succeed? Cytokinetics Heart Failure Trial Proves Too Much For FDA Committee
• By Michael McCaughan
Cytokinetics couldn’t leverage its large, successful trial for omecamtiv mecarbil into a positive vote at a FDA advisory committee. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
